404 completed, 63 terminated, 48 unknown, 41 recruiting. 596 Phase 3, 119 Phase 2.
Follow Behavioral Symptoms: new trials by email Literature Review of Behavioral Symptoms trials Research Report on Behavioral Symptoms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment Sildenafil - Cancer | Phase 2 / Phase 3 | Not yet recruiting | The University of Texas Medical Branch, Galveston | 30 | 2027-06-15 | 2026-05-11 |
| A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial Neuronavigated robotic-enabled TMS, NRX-101, Sham TMS - Treatment Resistant Depression, Treatment Resistant Depression (TRD) | Phase 2 / Phase 3 | Recruiting | NeuroRx, Inc. | 240 | 2026-12-01 | 2026-10-21 |
| Morphine or Ketamine for Analgesia Ketamine hydrochloride, Morphine sulphate - Abdominal Pain, Isolated Extremity Fracture | Phase 3 | Recruiting | Columbia University | 1010 | 2026-10-17 | 2026-10-20 |
| Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athletes With Co-morbid Depression and Concussion ONE-D TMS protocol and d-cycloserine (125 mg) - Concussion, Depression | Phase 2 / Phase 3 | Not yet recruiting | University of Florida | 35 | 2026-09-01 | 2026-08-18 |
| Brexanolone Lifting Outcomes Of Moms LPCN 1154A, Placebo - Depression, Postpartum, Postpartum Depression (PPD) | Phase 3 | Recruiting | Lipocine Inc. | 120 | 2026-09-01 | 2026-09-16 |
| Lumateperone for Late-Life Depression Lumateperone, Placebo - Treatment Resistant Depression (TRD), Late Life Depression (LLD) | Phase 3 | Recruiting | Eric Lenze | 100 | 2026-09-01 | 2026-09-16 |
| A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder Brenipatide, Placebo - Depressive Disorder, Major | Phase 3 | Recruiting | Eli Lilly and Company | 1000 | 2026-08-14 | 2026-11-03 |
| Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression Psilocybin - Major Depression | Phase 3 | Recruiting | VA Office of Research and Development | 240 | 2026-08-03 | 2026-10-23 |
| Allopurinol in Depression Sertraline 50 MG, Allopurinol 300 MG - Depression | Phase 2 / Phase 3 | Recruiting | Tanta University | 70 | 2026-05-20 | 2026-08-18 |
| Brief Cognitive Behavioral Therapy for Suicide Prevention in a Brazilian Sample: a Study Protocol of a Randomized Clinical Trial Brief Cognitive-Behavioral Therapy (BCBT) for Suicide Prevention, Supportive Therapy - Suicide Ideation, Suicide Attempts | Phase 3 | Not yet recruiting | University of Sao Paulo | 150 | 2026-05-10 | 2026-05-08 |
| InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression Ketamine, Oculus VR headset - Treatment Resistant Depression | Phase 3 | Recruiting | Sunnybrook Health Sciences Centre | 31 | 2026-05-03 | 2026-10-23 |
| To Evaluate the Efficacy, Safety, and Tolerability of Dronabinol Oral Solution for Agitation in Patients With Alzheimer's Disease Dronabinol Oral Solution, Placebo Control - Agitation in Dementia | Phase 2 / Phase 3 | Not yet recruiting | Benuvia Therapeutics Inc. | 140 | 2026-05-01 | 2026-02-25 |
| A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression Placebo group, JS1-1-01 low-dose group, JS1-1-01 high-dose group - Depression | Phase 2 / Phase 3 | Not yet recruiting | Tasly Pharmaceutical Group Co., Ltd | 180 | 2026-04-30 | 2026-04-08 |
| Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth N-acetylcysteine, Mindfulness-based cognitive therapy, Placebo - Mild Depression | Phase 3 | Recruiting | University of Cincinnati | 160 | 2026-02-26 | 2026-03-11 |
| REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool Senseye Diagnostic Tool (DT), Clinician Administered PTSD Scale for DSM-5, Revised Version - PTSD - Post Traumatic Stress Disorder | Phase 3 | Recruiting | Senseye, Inc. | 1900 | 2026-02-23 | 2026-04-29 |
| A Study of Brenipatide in Adult Participants With Major Depressive Disorder Brenipatide, Placebo - Depressive Disorder, Major | Phase 3 | Recruiting | Eli Lilly and Company | 1000 | 2026-02-09 | 2026-11-04 |
| A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder CYB003, Psychological Support - Major Depressive Disorder (MDD), Depression in Adults | Phase 3 | Recruiting | Cybin IRL Limited | 330 | 2025-12-10 | 2026-11-02 |
| A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) KarXT, KarX-EC - Alzheimer Disease, Agitation | Phase 3 | Recruiting | Bristol-Myers Squibb | 650 | 2025-12-02 | 2026-10-16 |
| Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) CYB003 - Major Depressive Disorder | Phase 3 | Enrolling by invitation | Cybin IRL Limited | 468 | 2025-07-18 | 2026-09-25 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo - Alzheimer's Disease | Phase 3 | Recruiting | Bristol-Myers Squibb | 426 | 2025-07-16 | 2026-11-03 |
Showing 20 of 596. Sign in to see all of them.
Depression (460) · Depressive Disorder, Major (184) · Depressive Disorder (56) · Psychomotor Agitation (54) · Anxiety Disorders (52) · Bipolar Disorder (39) · Alzheimer Disease (31) · Suicidal Ideation (28) · Stress Disorders, Post-Traumatic (25) · Dementia (19) · Mood Disorders (18) · Psychotic Disorders (17) · Depressive Disorder, Treatment-Resistant (15) · Mental Disorders (15) · Pain (14)
Behavior (592) · Mental Disorders (407) · Mood Disorders (235) · Depressive Disorder (164) · Pathological Conditions, Signs and Symptoms (136) · Signs and Symptoms (121) · Nervous System Diseases (115) · Neurologic Manifestations (100) · Neurobehavioral Manifestations (76) · Aberrant Motor Behavior in Dementia (63) · Central Nervous System Diseases (59) · Brain Diseases (55) · Dyskinesias (54) · Psychomotor Disorders (54)
Escitalopram (36) · Ketamine (27) · Sertraline (22) · Vortioxetine (16) · Cognitive Behavioral Therapy (14) · Fluoxetine (14) · Paroxetine (14) · Aripiprazole (12) · Duloxetine Hydrochloride (12) · Venlafaxine Hydrochloride (11) · Dexmedetomidine (10) · Quetiapine Fumarate (10) · SR 48968 (10) · Citalopram (9) · Midazolam (9)
Otsuka Pharmaceutical Development & Commercialization, Inc. (21) · Sanofi (18) · AstraZeneca (14) · Forest Laboratories (14) · Wyeth is now a wholly owned subsidiary of Pfizer (13) · Takeda (10) · Axsome Therapeutics, Inc. (8) · Massachusetts General Hospital (8) · Sumitomo Pharma America, Inc. (8) · University of Pennsylvania (8) · University of Pittsburgh (7) · Eli Lilly and Company (6) · GlaxoSmithKline (6) · University of Washington (6) · VA Office of Research and Development (6)
United States (360) · Canada (67) · France (46) · Germany (41) · Poland (40) · United Kingdom (33) · Bulgaria (27) · Spain (27) · Australia (25) · Russia (25) · Puerto Rico (24) · Serbia (24) · Ukraine (24) · Croatia (23) · Mexico (23)
Carl Gommoll, MS (5) · Katherine Beebe, PhD (5) · David Mischoulon, MD, PhD (4) · Jenna Hoogerheyde (4) · Sanjeev Pathak, MD (4)
PMID 34817851, PMID 31577867, PMID 24067192, PMID 24816198, PMID 26474010, PMID 26644957, PMID 30508090, PMID 33884617, PMID 36708956, PMID 37656180, PMID 40681915, PMID 41533472, PMID 41961243, PMID 23485955, PMID 23497790, PMID 24175720, PMID 24571916, PMID 25080392, PMID 25758058, PMID 26644956, PMID 26709542, PMID 29140227, PMID 29523415, PMID 34183490, PMID 37099968, PMID 38421922, PMID 39108660, PMID 40607746, PMID 40852147, PMID 41055581, PMID 41591746, PMID 20732631, PMID 21731831, PMID 22027845, PMID 23673347, PMID 24138011, PMID 24507016, PMID 25272149, PMID 25602163, PMID 25980552, PMID 27208498, PMID 29163985, PMID 30419989, PMID 31708380, PMID 31818787, PMID 31969269, PMID 32942346, PMID 33546709, PMID 33677183, PMID 33915374
2008 (8), 2009 (5), 2023 (5), 2017 (4), 2016 (3), 2025 (3), 2004 (2), 2014 (2), 2018 (2), R01MH121632 (2), U19MH098780 (2), 1RC2AG036535 (1), 2015 (1), F32MH075583 (1), I01CX000217 (1)